药企给出的巨额折扣 保司拿不到 患者用不了 商保创新药目录成了“摆设”？

Core Insights - The implementation of the first commercial health insurance innovative drug directory has raised concerns regarding hospital access, prescription issuance, and discount realization during claims processing [1][2] - The "three exclusions" policy from the National Healthcare Security Administration affects hospital decisions and attitudes towards the directory [1] - The current settlement process is complicated by the need for drug companies to maintain a unified public price, while insurance companies can only reimburse based on the invoice amount issued by medical institutions [2][3] Group 1: Challenges in Settlement - Hospitals can only issue "original price invoices," leading to insurance companies reimbursing at the original price, making discounts ineffective in actual settlements [2] - The discount pricing established through negotiations may become a "paper policy," failing to benefit either insurance companies or patients in practice [2] - The industry is actively seeking solutions to address the settlement bottleneck [2] Group 2: Innovative Solutions - A third-party TPA, Shangyong Technology, has successfully implemented a payment model where it pays the full price to hospitals on behalf of insurance companies, allowing for a claims process based on discounted amounts [3][19] - This model helps insurance companies reduce payout risks while providing value to patients and ensuring that innovative drugs fulfill their intended roles [5][19] - Another proposed solution involves a "dual platform and one channel" model that connects healthcare insurance and commercial insurance data, facilitating direct claims processing [8][9] Group 3: Regulatory and Operational Considerations - The "dual platform and one channel" system is designed to streamline claims for commercial insurance patients, allowing for real-time calculations and direct payments to hospitals [8][9] - The implementation of this system is currently limited to small, frequent, and standardized claims, which may not be suitable for high-value innovative therapies that require longer treatment cycles [12][13] - Regulatory constraints and the need for compliance with financial oversight present significant challenges to the scalability of these innovative payment models [21][22] Group 4: Industry Perspectives - Insurance companies prefer standardized management through official platforms rather than dealing with multiple TPA institutions, which increases operational costs [23] - The commercial insurance innovative drug directory includes 19 drugs that were previously eligible for coverage, but low reimbursement rates were due to access issues [24] - The exploration of settlement pathways for commercial insurance innovative drugs is crucial for the successful implementation of the directory [24]